Patents by Inventor Frank W. LoGerfo

Frank W. LoGerfo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220281802
    Abstract: Compounds, pharmaceutical compositions, and methods are disclosed for inhibiting interaction between IL18 and IL18R.
    Type: Application
    Filed: July 31, 2020
    Publication date: September 8, 2022
    Inventors: Leena PRADHAN-NABZDYK, Lijun SUN, Philip LOGERFO, Finith JERNIGAN, Gabriel BIRANNE, Frank W. LOGERFO
  • Patent number: 8119400
    Abstract: In particular embodiments, the present invention provides methods of inhibiting smooth muscle cell responses and methods of treating or preventing vascular proliferative disease caused by smooth muscle cell migration and proliferation. More specifically, smooth muscle cell responses are inhibited by introducing an agent into smooth muscle cells, wherein the agent inhibits an activity of one or more members of the myristoylated alanine-rich C kinase substrate (MARCKS) family of proteins. The invention also provides methods of inhibiting expression of one or more genes encoding a member of the MARCKS family of proteins in a cell.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: February 21, 2012
    Assignee: Beth Isreal Deaconess Medical Center, Inc.
    Inventors: Thomas S. Monahan, Frank W. LoGerfo, Nicholas D. Andersen
  • Publication number: 20080299654
    Abstract: In particular embodiments, the present invention provides methods of inhibiting smooth muscle cell responses and methods of treating or preventing vascular proliferative disease caused by smooth muscle cell migration and proliferation. More specifically, smooth muscle cell responses are inhibited by introducing an agent into smooth muscle cells, wherein the agent inhibits an activity of one or more members of the myristoylated alanine-rich C kinase substrate (MARCKS) family of proteins. The invention also provides methods of inhibiting expression of one or more genes encoding a member of the MARCKS family of proteins in a cell.
    Type: Application
    Filed: August 3, 2007
    Publication date: December 4, 2008
    Inventors: Thomas S. Monahan, Frank W. LoGerfo, Nicholas D. Andersen
  • Patent number: 7037527
    Abstract: The invention features a method of treating polyester material to generate functional carboxylic acid and amine groups. These functional groups can be used as sites for covalent bond formation to attach chemical or biological moieties. This bifunctionalized polyester polymer can be used in any medical application in which biocompatible polymers are used.
    Type: Grant
    Filed: January 27, 2003
    Date of Patent: May 2, 2006
    Assignees: University of Rhode Island, Beth Israel Deaconess Medical Center, BioMod Surfaces
    Inventors: Martin J. Bide, Matthew D. Phaneuf, William C. Quist, Donald J. Dempsey, Frank W. LoGerfo
  • Patent number: 6743253
    Abstract: Provided is a biocompatible device which has been coated or sealed with a polyether or polyether/carbonate based urethane polymer that contains functional groups (e.g. carboxylic acid groups) which are capable of serving as anchor sites for protein binding.
    Type: Grant
    Filed: February 28, 2001
    Date of Patent: June 1, 2004
    Assignees: BioMod Surfaces, Beth Israel Deaconess Medical Center
    Inventors: Matthew D. Phaneuf, Donald J. Dempsey, William C. Quist, Frank W. Logerfo
  • Publication number: 20040091604
    Abstract: The present invention is a broadly applicable methodology for making a bioactive titanium surface which would be clinically-acceptable and effective as either an anti-thrombin, thrombolytic or growth promoting surface coating, or any combination of these. The bioactive surface can be prepared using any material comprising titanium in whole or in part; is suitable for inclusion upon the exposed surfaces of surgically implantable prostheses comprising titanium; offers a means for avoiding systemic anticoagulation therapy to reduce thrombus formation and thromboembolism in the living subject receiving a surgically implanted prosthesis; and provides a means to induce cellular attachment and proliferation onto the titanium surface of the implant.
    Type: Application
    Filed: May 15, 2003
    Publication date: May 13, 2004
    Inventors: Donald J. Dempsey, William C. Quist, Lori M. Anderson, Matthew D. Phaneuf, Frank W. LoGerfo
  • Publication number: 20030216524
    Abstract: The invention features a method of treating polyester material to generate functional carboxylic acid and amine groups. These functional groups can be used as sites for covalent bond formation to attach chemical or biological moieties. This bifunctionalized polyester polymer can be used in any medical application in which biocompatible polymers are used.
    Type: Application
    Filed: January 27, 2003
    Publication date: November 20, 2003
    Inventors: Martin J. Bide, Matthew D. Phaneuf, William C. Quist, Donald J. Dempsey, Frank W. LoGerfo
  • Patent number: 6592885
    Abstract: The present invention provides a method for making an infection-resistant fabricated textile article which is suitable for any in-vivo usage either as a topical bandage, on an implantable configured construct, or as part of a prosthetic mechanical appliance. The method of manufacture applies broadly to any and all fabrics, cloths, gauzes, and/or films comprised in whole or in part of fibers; and provides an infection-resistant textile of valued use in a wide range and variety of medical applications.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: July 15, 2003
    Inventors: Matthew D. Phaneuf, William C. Quist, Martin J. Bide, Frank W. LoGerfo
  • Publication number: 20030091616
    Abstract: The present invention provides a method for making an infection-resistant fabricated textile article which is suitable for any in-vivo usage either as a topical bandage, on an implantable configured construct, or as part of a prosthetic mechanical appliance. The method of manufacture applies broadly to any and all fabrics, cloths, gauzes, and/or films comprised in whole or in part of fibers; and provides an infection-resistant textile of valued use in a wide range and variety of medical applications.
    Type: Application
    Filed: June 7, 2001
    Publication date: May 15, 2003
    Inventors: Matthew D. Phaneuf, William C. Quist, Martin J. Bide, Frank W. LoGerfo
  • Publication number: 20010053933
    Abstract: Provided is a biocompatible device which has been coated or sealed with a polyether or polyether/carbonate based urethane polymer that contains functional groups (e.g. carboxylic acid groups) which are capable of serving as anchor sites for protein binding.
    Type: Application
    Filed: February 28, 2001
    Publication date: December 20, 2001
    Inventors: Matthew D. Phaneuf, Donald J. Dempsey, William C. Quist, Frank W. Logerfo
  • Publication number: 20010049422
    Abstract: The invention provides urethane polymers bonded to therapeutically active compounds, such as antibiotics. The invention also features methods of applying therapeutically active compounds to polyurethane polymers using textile dyeing. These polymers may be used in a variety of clinical applications.
    Type: Application
    Filed: April 13, 2001
    Publication date: December 6, 2001
    Inventors: Matthew D. Phaneuf, William C. Quist, Michael Szycher, Martin J. Bide, Frank W. LoGerfo
  • Patent number: 5281662
    Abstract: Disclosed is a treated material including a base material such as an extrudate, a woven fabric, or unwoven fibers, a disperse dye-type molecule such as a dye or antibiotic dispersed within and non-covalently adhered to the base material, and a molecule-of-interest immobilized on the base material by way of a reactive group on the disperse dye-type molecule. Also disclosed are methods of producing the treated material.
    Type: Grant
    Filed: June 21, 1991
    Date of Patent: January 25, 1994
    Assignee: New England Deaconess Hospital Corporation
    Inventors: Ralph K. Ito, Frank W. LoGerfo
  • Patent number: 5167960
    Abstract: Disclosed is a biocompatible, thromboresistant substance useful for implantable and extracorpeoreal devices in contact with the vascular system, and methods for producing the same. The biocompatible, thromboresistant substance comprises a synthetic, biocompatible material, at least one biocompatible base coat layer adhered to at least one surface of the material, and a thrombogenesis inhibitor immobilized on the base coat layer via a component capable of binding the inhibitor. The thrombogenesis inhibitor is hirudin, or an active analog or fragment thereof.
    Type: Grant
    Filed: August 3, 1988
    Date of Patent: December 1, 1992
    Assignee: New England Deaconess Hospital Corporation
    Inventors: Ralph K. Ito, Frank W. LoGerfo
  • Patent number: 5126140
    Abstract: Disclosed is a biocompatible, thromboresistant substance useful for implantable and extracorporeal devices in contact with the vascular system, and methods for producing the same. The biocompatible, thromboresistant substance comprises a synthetic, biocompatible material, at least one biocompatible base coat layer adhered to at least one surface of the material, and the thrombogenesis inhibitor thrombomodulin immobilized on the base coat layer via a component capable of binding the inhibitor without affecting its thrombogenesis-inhibiting activity.
    Type: Grant
    Filed: July 24, 1989
    Date of Patent: June 30, 1992
    Assignee: New England Deaconess Hospital Corporation
    Inventors: Ralph K. Ito, Frank W. LoGerfo
  • Patent number: 5112615
    Abstract: Disclosed is a soluble, biocompatible, pharmacological agent for inhibiting thrombin generation and thrombus formation, and methods for producing the same. The pharmacological agent or conjugate includes a soluble, biocompatible carrier and a thrombogenesis inhibitor immobilized thereto via the carrier which binds the inhibitor. The thrombogenesis inhibitor is hirudin, or an active analog or active fragment thereof. The thrombogenesis inhibitor may be bound to the carrier via a bifunctional cross-linking reagent.
    Type: Grant
    Filed: October 4, 1990
    Date of Patent: May 12, 1992
    Assignee: New England Deaconess Hospital Corporation
    Inventors: Ralph K. Ito, Frank W. LoGerfo
  • Patent number: 5019393
    Abstract: Disclosed is a biocompatible, thromboresistant substance useful for implantable and extracorporeal devices in contact with the vascular system, and methods for producing the same. The biocompatible, thromboresistant substance comprises a synthetic, biocompatible material, at least one biocompatible base coat layer adhered to at least one surface of the material, and a thrombogenesis inhibitor immobilized on the base coat layer via a component capable of binding the inhibitor. The thrombogenesis inhibitor is streptokinase, urokinase, tissue plasminogen activator, ATPase, 5'-nucleotidase, and active fragments and active analogs thereof.
    Type: Grant
    Filed: August 3, 1988
    Date of Patent: May 28, 1991
    Assignee: New England Deaconess Hospital Corporation
    Inventors: Ralph K. Ito, Frank W. LoGerfo